LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Puma Biotechnology Inc

Затворен

СекторЗдравеопазване

3.34 2.77

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.25

Максимум

3.51

Ключови измерители

By Trading Economics

Приходи

-16M

3M

Продажби

-13M

46M

P/E

Средно за сектора

4.903

56.602

EPS

0.1

Марж на печалбата

6.464

Служители

172

EBITDA

-14M

4M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+49.31% upside

Дивиденти

By Dow Jones

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-8.4M

151M

Предишно отваряне

0.57

Предишно затваряне

3.34

Настроения в новините

By Acuity

60%

40%

328 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Puma Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.05.2025 г., 19:39 ч. UTC

Значими двигатели на пазара

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16.05.2025 г., 23:18 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16.05.2025 г., 22:30 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- Update

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.05.2025 г., 21:54 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- WSJ

16.05.2025 г., 21:22 ч. UTC

Пазарно говорене

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Пазарно говорене

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Топ новини

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16.05.2025 г., 21:05 ч. UTC

Пазарно говорене

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16.05.2025 г., 20:55 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.05.2025 г., 20:37 ч. UTC

Топ новини

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16.05.2025 г., 20:33 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16.05.2025 г., 20:18 ч. UTC

Топ новини

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16.05.2025 г., 20:16 ч. UTC

Топ новини

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16.05.2025 г., 20:15 ч. UTC

Печалби

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16.05.2025 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: William K. Daniel Joins Board

16.05.2025 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: Strategic Investment by KKR Completed

16.05.2025 г., 20:05 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16.05.2025 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

16.05.2025 г., 18:51 ч. UTC

Топ новини

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16.05.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 18:37 ч. UTC

Пазарно говорене

Gold Futures End Week on Negative Note -- Market Talk

16.05.2025 г., 18:35 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16.05.2025 г., 18:32 ч. UTC

Топ новини

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16.05.2025 г., 18:28 ч. UTC

Пазарно говорене

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Puma Biotechnology Inc Прогноза

Ценова цел

By TipRanks

49.31% нагоре

12-месечна прогноза

Среден 4.33 USD  49.31%

Висок 7 USD

Нисък 2 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Puma Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

1

Купи

1

Задържане

1

Продай

Техническа оценка

By Trading Central

3.07 / 3.075Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

328 / 382 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.